GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...

Intensive blood pressure control in patients with chronic kidney disease showed cardiovascular benefits in real-world ...

His groundbreaking discovery of how cortisol acts through mineralocorticoid receptors (MR) and glucocorticoid receptors (GR) has revolutionized our understanding of stress-related mental health ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.